Japan’s contract drug rep ratio rose to 8.7% in FY2024 as the total number of regular reps continued to fall, the Japan Contract Sales Organization Association (JCSOA) reported in June. Amid industry downsizing, the roles and expectations placed on contract…
To read the full story
Related Article
- Genmab Japan to Expand into Solid Tumors, Boost Focus on Gyn/Onc: Chief
November 22, 2024
- 2 Cancer Meds in PIII, Genmab to Rev Up Rep Hiring to Build Sales Regime in Japan
December 2, 2022
- Genmab to Branch Out into 2nd Disease Area beyond Cancer, Specifics to Be Unveiled Next Year: CEO
October 24, 2022
- Genmab Poised to Triple Japan Staff for Stand-Alone Biz, First Up Is ADC for Cervical Cancer
January 22, 2021
BUSINESS
- Sanofi Begins Japan PII for Type 1 Diabetes Med Teplizumab
August 22, 2025
- Meiji Group Launches PII Trial of Dengue Vaccine in Thailand
August 22, 2025
- Itochu Launches J-STEP to Help Overseas Drug Makers Tackle Japan’s “Drug Loss”
August 21, 2025
- ASKA, MICIN Team Up to Develop IBS Treatment App
August 21, 2025
- AnGes Taps Boehringer for Collategene Manufacturing
August 21, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…